|
 |
| home > ebr > spring 2004 > a review of burrill & company's 18th annual report on the biotech industry |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
| "While revaluation and restructuring defined 2002, the biotech industry made a dramatic recovery in 2003 getting 'back on track'", notes G Steven Burrill at the start of Burrill & Company's 18th annual report on the biotechnology industry. The 450 page compendium details all the important events, discoveries and financial activity in the various sectors of the biotechnology industry during 2003. G Steven Burrill, CEO of Burrill & Company and a respected biotech investment visionary, identifies the key trends and outlook for this increasingly vital and important industry. Burrill's book is a valuable resource of state-of-the-industry data and statistics with insight on where the various areas of the life sciences are headed. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
EuroBiopartnering 2008
7-9 October 2008, Paris, France
EuroBiOpartnering
2008 gives you the unique opportunity to meet the relevant decision makers and
opinion leaders from the international biotech community and offers you 3 days
of partnering opportunities including one-to-one meetings, company presentations
and further networking activities…
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
 |
